NCT07529535 2026-04-15
A Phase I/II Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Phase 1 Suspended
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Cancer Research UK
University of Chicago
BioRay Pharmaceutical Co., Ltd.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University